Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ)
CNY 18.83
(1.4%)
CNY 18.83
(1.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 305.1 Million CNY | -10.26% |
| 2022 | 283.28 Million CNY | 20.03% |
| 2021 | 238.18 Million CNY | 35.21% |
| 2020 | 173.61 Million CNY | 25.58% |
| 2019 | 138.25 Million CNY | 9.39% |
| 2018 | 125.41 Million CNY | 16.82% |
| 2017 | 108.4 Million CNY | 11.83% |
| 2016 | 91.04 Million CNY | 0.0% |
| 2014 | 74.12 Million CNY | 7.62% |
| 2013 | 67.74 Million CNY | 6.91% |
| 2012 | 57.74 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 31.12 Million CNY | -60.98% |
| 2024 Q2 | 71.52 Million CNY | 156.18% |
| 2024 Q3 | 44.47 Million CNY | -44.23% |
| 2023 Q2 | 73.29 Million CNY | -10.77% |
| 2023 Q3 | 42.96 Million CNY | -41.38% |
| 2023 Q4 | 63.39 Million CNY | 47.56% |
| 2023 FY | - CNY | -10.26% |
| 2023 Q1 | 82.14 Million CNY | 79.54% |
| 2022 Q3 | 85.03 Million CNY | 44.28% |
| 2022 FY | - CNY | 20.03% |
| 2022 Q4 | 45.75 Million CNY | -46.2% |
| 2022 Q2 | 58.93 Million CNY | 2.35% |
| 2022 Q1 | 57.58 Million CNY | 8.98% |
| 2021 Q2 | 47.26 Million CNY | -5.91% |
| 2021 Q1 | 50.22 Million CNY | 13.07% |
| 2021 Q4 | 52.84 Million CNY | 8.22% |
| 2021 FY | - CNY | 35.21% |
| 2021 Q3 | 48.82 Million CNY | 3.31% |
| 2020 Q3 | 43.27 Million CNY | -0.21% |
| 2020 Q1 | 36.2 Million CNY | 11.83% |
| 2020 FY | - CNY | 25.58% |
| 2020 Q2 | 43.37 Million CNY | 19.8% |
| 2020 Q4 | 44.42 Million CNY | 2.64% |
| 2019 Q2 | 31.88 Million CNY | 0.0% |
| 2019 FY | - CNY | 9.39% |
| 2019 Q4 | 32.37 Million CNY | -11.76% |
| 2019 Q3 | 36.68 Million CNY | 15.08% |
| 2019 Q1 | 31.88 Million CNY | 0.0% |
| 2018 FY | - CNY | 16.82% |
| 2017 FY | - CNY | 11.83% |
| 2016 FY | - CNY | 0.0% |
| 2014 FY | - CNY | 7.62% |
| 2013 FY | - CNY | 6.91% |
| 2012 FY | - CNY | 0.0% |